Biotech Bear Market Looking For Relief From Q3 Large Cap Growth

Biotech Bear Market-Stocks Remain Weighed Down By Pricing Rhetoric

Can Large Cap Biopharma Deliver Growth to Spark the Sector?

On October 12, I reviewed Key Trends to watch that might portend a Q4 rally.Here is a quick review of those trends:

  1. Momentum remains weak with successive days of the dreaded red screen. Although trading is active most stocks remain weak and are down YTD. Today a mixed market offers glimpses of green in large and mid-caps, but many MO stocks are down: BLUE, JUNO, PBYI, RDUS, TSRO, etc. Even ALKS is down after a great start for the week.
  2. Technicals have gotten worse with the IBB at $265 below support of $270 but still 25 points above the BREXIT bottom. The XBI broke support of $60 and now at $58 is only 8 points above the BREXIT bottom. The bellwether stock Celgene (CELG) illustrates the bear condition down 18% YTD and 7.4% over the past month but up today.
  3. Earnings from several large cap biopharma companies are coming up beginning this week so we will get a clearer picture of revenue growth. Vertex (VRTX) was down almost 2% today to the 77 level near its 52 week low on lower than expected Q3 results but bounced back. Sales for Cystic Fibrosis drugs rose 34% and losses were lowered to $41.8M. Biogen (BIIB) was up 3.6% on better Q3 Net of $1B due to lower costs and higher revenues of MS drugs to  $3B, 6% over same quarter in previous year. AMGN, BMY and CELG will report tomorrow.
  4. The healthcare sector (XLV) remains under a barrage of market and political pressures on drug pricing. The healthcare sector is among the weakest YTD,  down 4.7% over one month in a downward trajectory compared to the S&P up 4.4% YTD. The Nasdaq recently hit new highs YTD and is now up 4.7% bolstered by tech stocks.
  5. M&A is still the major driver of selected stocks with the “food chain” effect in place. Companies can complement revenue growth and fortify market positions with pipeline acquisitions. Since “inversion” deals have been made uneconomical by new government rulings U.S. deals are picking up like Medivation (MDVN) $14B deal with Pfizer (PFE). Various M&A sessions from the BIO Investor Forum were also encouraged by M&A prospects.(more to come on M&A)
1 2
View single page >> |

Disclosure: None

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.
Chee Hin Teh 4 years ago Member's comment

thanks for sharing

Chee Hin Teh 4 years ago Member's comment

Thanks for sharing

Chee Hin Teh 4 years ago Member's comment

thanks for sharing